Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–asses...

por Warren, R.B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., Paul, C.
Publicado 2020

Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis

por Truong, B, Rich-Garg, N, Ehst, BD, Deodhar, AA, Ku, JH, Vakil-Gilani, K, Danve, A, Blauvelt, A
Publicado 2015

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

por Blauvelt, A., Sofen, H., Papp, K., Gooderham, M., Tyring, S., Zhao, Y., Lowry, S., Mendelsohn, A., Parno, J., Reich, K.
Publicado 2019

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials

por Blauvelt, A., Reich, K., Lebwohl, M., Burge, D., Arendt, C., Peterson, L., Drew, J., Rolleri, R., Gottlieb, A.B.
Publicado 2018

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III stu...

por Kimball, A.B., Papp, K.A., Reich, K., Gooderham, M., Li, Q., Cichanowitz, N., La Rosa, C., Blauvelt, A.
Publicado 2019

Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial

por Warren, R. B., Lebwohl, M., Sofen, H., Piguet, V., Augustin, M., Brock, F., C. Arendt, Fierens, F., Blauvelt, A.
Publicado 2021

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

por Kimball, A.B., Kerbusch, T., van Aarle, F., Kulkarni, P., Li, Q., Blauvelt, A., Papp, K.A., Reich, K., Montgomery, D.
Publicado 2019

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐wee...

por Blauvelt, A., Reich, K., Mehlis, S., Vanaclocha, F., Sofen, H., Abramovits, W., Zhao, Y., Gilloteau, I., Davenport, E., Williams, N., Guana, A., Tyring, S.
Publicado 2017

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

por Papp, K.A., Blauvelt, A., Kimball, A.B., Han, C., Randazzo, B., Wasfi, Y., Shen, Y.‐K., Li, S., Griffiths, C.E.M.
Publicado 2018

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a doubl...

por Bagel, J., Blauvelt, A., Nia, J., Hashim, P., Patekar, M., de Vera, A., Ahmad, K., Paguet, B., Xia, S., Muscianisi, E., Lebwohl, M.
Publicado 2020

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

por Gordon, K.B., Warren, R.B., Gottlieb, A.B., Blauvelt, A., Thaçi, D., Leonardi, C., Poulin, Y., Boehnlein, M., Brock, F., Ecoffet, C., Reich, K.
Publicado 2020

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-mar...

por Deodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., Pricop, L., Fox, T.
Publicado 2019

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

por Blauvelt, A., Paul, C., van de Kerkhof, P., Warren, R.B., Gottlieb, A.B., Langley, R.G., Brock, F., Arendt, C., Boehnlein, M., Lebwohl, M., Reich, K.
Publicado 2020

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials

por Blauvelt, A., Rosmarin, D., Bieber, T., Simpson, E.L., Bagel, J., Worm, M., Deleuran, M., Katoh, N., Kawashima, M., Shumel, B., Chen, Z., Rossi, A.B., Hultsch, T., Ardeleanu, M.
Publicado 2019

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

por Gordon, K.B., Lebwohl, M., Papp, K.A., Bachelez, H., Wu, J.J., Langley, R.G., Blauvelt, A., Kaplan, B., Shah, M., Zhao, Y., Sinvhal, R., Reich, K.
Publicado 2021

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

por Blauvelt, A., Papp, K.A., Sofen, H., Augustin, M., Yosipovitch, G., Katoh, N., Mrowietz, U., Ohtsuki, M., Poulin, Y., Shrom, D., Burge, R., See, K., Mallbris, L., Gordon, K.B.
Publicado 2017

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 1...

por Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.
Publicado 2019

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

por Wollenberg, A., Beck, L.A., Blauvelt, A., Simpson, E.L., Chen, Z., Chen, Q., Shumel, B., Khokhar, F.A., Hultsch, T., Rizova, E., Rossi, A.B., Graham, N.M.H., Pirozzi, G., Lu, Y., Ardeleanu, M.
Publicado 2019

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, doubl...

por Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K.B., Ferris, L.K., Langley, R.G., Tada, Y., Lima, R.G., Elmaraghy, H., Gallo, G., Renda, L., Park, S.Y., Burge, R., Bagel, J.
Publicado 2020

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded t...

por Blauvelt, A., Leonardi, C., Elewski, B., Crowley, J.J., Guenther, L.C., Gooderham, M., Langley, R.G., Vender, R., Pinter, A., Griffiths, C.E.M., Tada, Y., Elmaraghy, H., Lima, R.G., Gallo, G., Renda, L., Burge, R., Park, S.Y., Zhu, B., Papp, K.
Publicado 2020